3
Announcements
Trials
Browse
Landscape
Status
No longer available
3
Approved for marketing
1
Sponsor Class
INDUSTRY
3
Study Type
Expanded_access
3
Sponsor
Cancer Type
Dermatologic
2
Thoracic
1
Conditions
Melanoma
2
Squamous Non-Small Cell Lung Cancer
1
Interventions
trametinib
4
nilotinib
4
elotuzumab
4
dabrafenib
4
Amifampridine
4
regorafenib
3
pembrolizumab
3
midostaurin
3
fludarabine phosphate
3
fludarabine
3
Nivolumab
3
Lenalidomide
3
Ipilimumab
3
Everolimus
3
Dexamethasone
3
Cyclophosphamide
3
Crizotinib
3
Bortezomib
3
Axitinib
3
venetoclax
2
veliparib
2
tazemetostat
2
talimogene laherparepvec
2
navitoclax
2
gallium 68 PSMA-11
2
ceritinib
2
carbon-11 acetate
2
aldesleukin
2
Whole-Body Irradiation
2
Trabectedin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
No longer available
×
Expanded_access
×
Nivolumab
×
Clear all
NCT06590480
2025-12-18
RPL-EAP-001
Replimune, Inc.
No longer available
NCT02475382
2020-11-27
CheckMate 169
Bristol-Myers Squibb
No longer available
NCT02186249
2017-02-08
CheckMate218
Bristol-Myers Squibb
No longer available